J&J, Bayer's Xarelto scores FDA nod in post-surgery artery disease as partners try...

[cafead]

via Trailing a big-selling rival from Pfizer and Bristol Myers Squibb, Bayer and Johnson & Johnson are looking for any opportunity to bolster their aging heart drug Xarelto. Now, just short of its 10th anniversary on the market, Xarelto will celebrate with another FDA win.

article source